Maël Heiblig

3.2k total citations · 1 hit paper
75 papers, 789 citations indexed

About

Maël Heiblig is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Maël Heiblig has authored 75 papers receiving a total of 789 indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Hematology, 32 papers in Genetics and 24 papers in Rheumatology. Recurrent topics in Maël Heiblig's work include Acute Myeloid Leukemia Research (33 papers), Otitis Media and Relapsing Polychondritis (19 papers) and Chronic Myeloid Leukemia Treatments (16 papers). Maël Heiblig is often cited by papers focused on Acute Myeloid Leukemia Research (33 papers), Otitis Media and Relapsing Polychondritis (19 papers) and Chronic Myeloid Leukemia Treatments (16 papers). Maël Heiblig collaborates with scholars based in France, United States and Italy. Maël Heiblig's co-authors include Xavier Thomas, Fiorenza Barraco, Estelle Bourbon, Pierre Sujobert, Yvan Jamilloux, Pierre Sujobert, Thomas Barba, Cécile‐Audrey Durel, P. Sève and Jean‐Christophe Lega and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Maël Heiblig

58 papers receiving 779 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Therapeutic options in VEXAS syndrome: insights from a retrospective series

2021 161 citations Estelle Bourbon, Maël Heiblig et al. Blood profile →

Peers

Countries citing papers authored by Maël Heiblig

Since Specialization

Citations

This map shows the geographic impact of Maël Heiblig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maël Heiblig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maël Heiblig more than expected).

Fields of papers citing papers by Maël Heiblig

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maël Heiblig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maël Heiblig. The network helps show where Maël Heiblig may publish in the future.

Co-authorship network of co-authors of Maël Heiblig

This figure shows the co-authorship network connecting the top 25 collaborators of Maël Heiblig. A scholar is included among the top collaborators of Maël Heiblig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maël Heiblig. Maël Heiblig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Establishing a consensus definition of VEXAS flare for clinical research 2025 ·Lara D. Veeken ·Lachelle D. Weeks, Danielle Hammond, Sinisa Savic, Maël Heiblig, Onima Chowdhury, A. Mékinian, Carmelo Gurnari, Radhakrishnan Ramchandren, Sophie Georgin‐Lavialle, Marcela A. Ferrada, Sarah Buckley, Bryan Harder, David B. Beck, Matthew J. Koster	0
2	Characterizing VEXAS syndrome in women: Findings from an international multicenter study 2025 ·Journal of Internal Medicine ·R. Bourguiba, Valentin Lacombe, David B. Beck, Eduardo Martín‐Nares, Vincent Jachiet, Thibault Comont, J. Galland, Maël Heiblig, (unknown), Achille Aouba, (unknown), Aurore Curie, Benjamin Terrier, (unknown), Matthew J. Koster, Yohei Kirino, Olivier Kosmider, A. Mékinian, Sophie Georgin‐Lavialle	0
3	Thrombocytosis drives alteration of primary hemostasis and acquired von willebrand syndrome occurrence in myeloproliferative neoplasms 2025 ·Blood ·(unknown), (unknown), (unknown), (unknown), Marie Balsat, Hélène Labussière‐Wallet, (unknown), Vincent Alcazer, Sophie Ducastelle-Leprêtre, Gaëlle Fossard, (unknown), Fiorenza Barraco, Lila Gilis, (unknown), Hervé Ghesquières, Christophe Nougier, Yesim Dargaud, Maël Heiblig	0
4	Real-World Multicenter Comparison of Venetoclax and Azacitidine Versus Intermediate or High Dose Cytarabine-Based Salvage for Patients with AML in First Relapse after Front Line Intensive Chemotherapy. a Dataml-IPC-Auraml Consortium Study 2024 ·Blood ·(unknown), Sarah Bertoli, (unknown), Maël Heiblig, Thibaut Leguay, Suzanne Tavitian, Éric Delabesse, (unknown), Emmanuelle Tavernier, Martin Carré, (unknown), Anne Banos, Norbert Vey, (unknown), Christian Récher, Sylvain Garciaz	0
5	Azacitidine and Venetoclax As a Salvage Therapy for Relapse after Allogeneic Transplantation for Acute Myeloid Leukemia : A Multicentric Study from French Auraml Group 2024 ·Blood ·Emmanuelle Tavernier, Jérôme Cornillon, (unknown), (unknown), (unknown), Martin Carré, (unknown), (unknown), (unknown), (unknown), (unknown), Sylvain Lamure, Amine Belhabri, Mauricette Michallet, Adrien Contejean, (unknown), Gian Matteo Pica, (unknown), Maël Heiblig	2
6	Odyssey: A First-in-Human Study of the Aldehyde Dehydrogenase (ALDH) Inhibitor Abd-3001 in Patients with Refractory/Relapsed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) 2024 ·Blood ·Lina Benajiba, (unknown), Maël Heiblig, (unknown), (unknown), (unknown), (unknown), (unknown), Geoffroy Venton, (unknown), (unknown), Gaëlle Fossard, (unknown), (unknown), İsmail Çeylan, (unknown), Jean‐Jacques Kiladjian, Régis Costello	1
7	Infectious Complications Among Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia: A Multicentric Real-Life Analysis of the French Auraml Group 2024 ·Blood ·Adrien Contejean, Pierre Chauvelot, (unknown), (unknown), Martin Carré, Emmanuelle Tavernier, Jérôme Cornillon, (unknown), (unknown), Sylvain Lamure, (unknown), (unknown), (unknown), Gian Matteo Pica, (unknown), Amine Belhabri, Mauricette Michallet, (unknown), Maël Heiblig	0
8	Impact of Age on Poly(ADP-Ribose) Polymerase Inhibitor (PARPi)-Induced Lymphopenia: A Scoping Review of the Literature and Internal Analysis of a Retrospective Database 2023 ·Drugs & Aging ·(unknown), Maël Heiblig, Gilles Freyer, Hervé Ghesquières, Claire Falandry	2
9	Hyperleukocytosis Increases the Risk of Early Relapses Independently of Genetics in AML 2023 ·Blood ·(unknown), Nicolas Duployez, (unknown), Juliette Lambert, Maël Heiblig, Mathilde Hunault, Claude Gardin, Stéphane de Botton, Élise Fournier, Cécile Pautas, Christine Terré, Éric Delabesse, Norbert Ifrah, Arnaud Pigneux, (unknown), Christian Récher, Claude Preudhomme, Hervé Dombret, Raphaël Itzykson	0
10	VEXAS syndrome, a new kid on the block of auto-inflammatory diseases: A hematologist's point of view 2023 ·Best Practice & Research Clinical Rheumatology ·Maël Heiblig, Bhavisha A. Patel, Yvan Jamilloux	4
11	Sickle cell disease and acute leukemia: one case report and an extensive review 2023 ·Annals of Hematology ·Giovanna Cannas, Solène Poutrel, Maël Heiblig, Hélène Labussière, (unknown), Xavier Thomas, A. Hot	7
12	Impact on Outcome of Minimal Residual Disease after Hematopoietic Stem Cell Transplantation with Fludarabine, Amsacrine, and Cytosine Arabinoside-Busulfan Conditioning: A Retrospective Monocentric Study 2022 ·Transplantation and Cellular Therapy ·(unknown), Adriana Pleșa, (unknown), Gaëlle Fossard, Fiorenza Barraco, (unknown), Marie Balsat, Sophie Ducastelle-Leprêtre, Lila Gilis, Xavier Thomas, Hervé Ghesquières, Isabelle Tigaud, Sandrine Hayette, Sarah Huet, Pierre Sujobert, (unknown), (unknown), Mauricette Michallet, Hélène Labussière‐Wallet, Maël Heiblig	4
13	Molecular heterogeneity and measurable residual disease of rare NPM1 mutations in acute myeloid leukemia: a nationwide experience from the GBMHM study group 2022 ·Leukemia ·Élise Fournier, Maël Heiblig, (unknown), Pascale Flandrin‐Gresta, (unknown), Laurent Miguet, Laurène Fenwarth, Laurent Vallat, (unknown), Alice Marceau‐Renaut, Adriana Pleșa, Claude Preudhomme, Pierre Sujobert, Sandrine Hayette, Nicolas Duployez, Sarah Huet	2
14	Class I/Class II HLA Evolutionary Divergence Ratio Is an Independent Marker Associated With Disease-Free and Overall Survival After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia 2022 ·Frontiers in Immunology ·(unknown), Valérie Dubois, Hélène Labussière‐Wallet, Fabienne Venet, Fiorenza Barraco, Sophie Ducastelle-Leprêtre, (unknown), Marie Balsat, Lila Gilis, Gaëlle Fossard, Hervé Ghesquières, Maël Heiblig, Florence Ader, Vincent Alcazer	15
15	Toward a pathophysiology inspired treatment of VEXAS syndrome 2021 ·Seminars in Hematology ·Maël Heiblig, Bhavisha A. Patel, Emma M. Groarke, Estelle Bourbon, Pierre Sujobert	45
16	Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience 2021 ·Blood Advances ·(unknown), Nicolas Duployez, Élise Fournier, Claude Preudhomme, Valérie Coiteux, Léonardo Magro, Bruno Quesnel, Maël Heiblig, Pierre Sujobert, Fiorenza Barraco, (unknown), (unknown), É. Hachulla, David Launay, Ibrahim Yakoub‐Agha, Louis Terriou	99
17	Long-term follow-up of de novo chronic phase chronic myelogenous leukemia patients on front-line imatinib 2018 ·Experimental Hematology ·Franck E. Nicolini, Vincent Alcazer, Pascale Cony‐Makhoul, Maël Heiblig, Stéphane Morisset, Gaëlle Fossard, Audrey Bidet, Anna Schmitt, Mohamad Sobh, Sandrine Hayette, François‐Xavier Mahon, Stéphanie Dulucq, Gabriel Étienne	6
18	Elderly Patients (Age 70 Years or Older) With Secondary Acute Myeloid Leukemia or Acute Myeloid Leukemia Developed Concurrently to Another Malignant Disease 2018 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), (unknown), (unknown), Mohamed Elhamri, Maël Heiblig, Alexandre Deloire, Sophie Ducastelle, Hélène Labussière, Fiorenza Barraco, Eric Wattel, Gilles Salles, Étienne Paubelle, Xavier Thomas	4
19	The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment 2016 ·Expert Opinion on Drug Discovery ·Xavier Thomas, Maël Heiblig	11
20	Major Molecular Response Achievement in CML Patients Can Be Predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS Ratio at an Earlier Time Point of Follow-Up than Currently Recommended 2014 ·PLoS ONE ·Sarah Huet, Pascale Cony‐Makhoul, Maël Heiblig, Isabelle Tigaud, Sophie Gazzo, Amine Belhabri, (unknown), Mauricette Michallet, Jean‐Pierre Magaud, Sandrine Hayette, Franck E. Nicolini	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact